(Q35648273)

9 August 2017

Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections (English)

1 reference

methicillin-resistant Staphylococcus aureus

9 August 2017

0 references

Staphylococcus aureus

1 reference

Fan W

1

1 reference

9 August 2017

del Busto R

2

1 reference

9 August 2017

Love M

3

1 reference

9 August 2017

Markowitz N

4

1 reference

9 August 2017

Cendrowski C

5

1 reference

9 August 2017

Cardenas J

6

1 reference

9 August 2017

Quinn E

7

1 reference

9 August 2017

Saravolatz L

8

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 1986

1 reference

Antimicrobial Agents and Chemotherapy

9 August 2017

1 reference

9 August 2017

29

1 reference

9 August 2017

26-29

1 reference

9 August 2017

1

1 reference

Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

In vitro activity of N-formimidoyl thienamycin and other beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

Imipenem versus moxalactam in the treatment of serious infections

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

In vitro susceptibility patterns of methicillin-resistant and-susceptible Staphylococcus auerues strains in a population of parenteral drug abusers from 1972 to 1981.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamcyin-dehydropeptidase inhibitor) and cefazolin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

Thienamycin: development of imipenen-cilastatin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

Susceptibility of Gram-Positive Cocci to Various Antibiotics, Including Cefotaxime, Moxalactam, and N -Formimidoyl Thienamycin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

Susceptibility of anaerobic bacteria to imipenem.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

Activity of imipenem on aerobic bacteria.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180357

In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria

25 September 2018

1 reference

12 December 2020

Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis

1 reference

12 December 2020

Comparative imipenem treatment of Staphylococcus aureus endocarditis in the rat

1 reference

12 December 2020

Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group

1 reference

12 December 2020

N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.29.1.26

1 reference

9 August 2017

1 reference

9 August 2017

1 reference